ArticleFrontiers in immunology2016
Activated Allogeneic NK Cells Preferentially Kill Poor Prognosis B-Cell Chronic Lymphocytic Leukemia Cells.
Open access · goldAbstract read
In one paragraph
Article in Frontiers in immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 30 citations in OpenAlex.
- Human pluripotent stem cell-derived innate and adaptive immune cells for cancer immunotherapy.Cell stem cell · 2026Review
- Dynamic Changes in miRNA Expression during the Generation of Expanded and Activated NK Cells.International journal of molecular sciences · 2023Article
- Natural Killer Cells in Chronic Lymphocytic Leukemia: Functional Impairment and Therapeutic Potential.Cancers · 2022Review
- Evaluation of allogeneic and autologous membrane-bound IL-21-expanded NK cells for chronic lymphocytic leukemia therapy.Blood advances · 2022Article
- Adoptive NK Cell Transfer as a Treatment in Colorectal Cancer Patients: Analyses of Tumour Cell Determinants Correlating With EfficacyFrontiers in immunology · 2022Article
- CAR T Cells Targeting Membrane-Bound Hsp70 on Tumor Cells Mimic Hsp70-Primed NK Cells.Frontiers in immunology · 2022Article
- Impact of Immune Parameters and Immune Dysfunctions on the Prognosis of Patients with Chronic Lymphocytic Leukemia.Cancers · 2021Review
- NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications.International journal of molecular sciences · 2021Review
- Intrinsic Resistance of Chronic Lymphocytic Leukemia Cells to NK Cell-Mediated Lysis Can Be OvercomeFrontiers in immunology · 2021Article
- Natural Killer Anti-Tumor Activity Can Be Achieved byFrontiers in immunology · 2021Article
- Expanded NK cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients.Oncoimmunology · 2020Article
- Expanded and activated allogeneic NK cells are cytotoxic against B-chronic lymphocytic leukemia (B-CLL) cells with sporadic cases of resistance.Scientific reports · 2020Article
- Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia.Frontiers in immunology · 2020Review
- NK Cells in the Treatment of Hematological Malignancies.Journal of clinical medicine · 2019Review
- Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia.International journal of molecular sciences · 2019Review
- Non-Genetically Improving the Natural Cytotoxicity of Natural Killer (NK) Cells.Frontiers in immunology · 2019Review
- Antigen-specific primed cytotoxic T cells eliminate tumour cells in vivo and prevent tumour development, regardless of the presence of anti-apoptotic mutations conferring drug resistance.Cell death and differentiation · 2018Article
- Expansion of allogeneic NK cells with efficient antibody-dependent cell cytotoxicity against multiple tumors.Theranostics · 2018Article
- Novel Strategy to Expand Super-Charged NK Cells with Significant Potential to Lyse and Differentiate Cancer Stem Cells: Differences in NK Expansion and Function between Healthy and Cancer Patients.Frontiers in immunology · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 8 institutions in 2 countries.
Diego Sánchez-MartínezBiomedical Research Center of Aragón (CIBA), Aragón Health Research Institute (IIS Aragón), University of Zaragoza , Zaragoza , Spain.
Pilar M LanuzaBiomedical Research Center of Aragón (CIBA), Aragón Health Research Institute (IIS Aragón), University of Zaragoza , Zaragoza , Spain.
Natalia GómezImmunogenetics and HLA, Instituto de Investigación Sanitaria Puerta de Hierro , Majadahonda , Spain.
Aura MuntasellImmunity and infection Lab, IMIM (Hospital del Mar Medical Research Institute) , Barcelona , Spain.
Elisa CisnerosImmunogenetics and HLA, Instituto de Investigación Sanitaria Puerta de Hierro , Majadahonda , Spain.
Manuela MoraruImmunogenetics and HLA, Instituto de Investigación Sanitaria Puerta de Hierro , Majadahonda , Spain.
Gemma AzacetaHospital Clínico Universitario Lozano Blesa, Instituto Aragonés de Ciencias de la Salud (IACS)/Aragón Health Research Institute (IIS Aragón) , Zaragoza , Spain.
Alberto AnelDepartment of Biochemistry and Molecular and Cellular Biology, Aragón Health Research Institute (IIS Aragón), University of Zaragoza , Zaragoza , Spain.
Luis Martínez-LostaoHospital Clínico Universitario Lozano Blesa, Instituto Aragonés de Ciencias de la Salud (IACS)/Aragón Health Research Institute (IIS Aragón), Zaragoza, Spain; Nanoscience Institute of Aragon (INA), University of Zaragoza, Zaragoza, Spain.
Martin VillalbaINSERM U1183, Université de Montpellier 1, UFR Médecine, Montpellier, France; Institute for Regenerative Medicine and Biotherapy (IRMB), CHU Montpellier, Montpellier, France.
Luis PalomeraHospital Clínico Universitario Lozano Blesa, Instituto Aragonés de Ciencias de la Salud (IACS)/Aragón Health Research Institute (IIS Aragón) , Zaragoza , Spain.
Carlos VilchesImmunity and infection Lab, IMIM (Hospital del Mar Medical Research Institute) , Barcelona , Spain.
José A García MarcoUnidad de Citogenética Molecular/Servicio de Hematología, Hospital Universitario Puerta de Hierro-Majadahonda , Madrid , Spain.
Julián PardoBiomedical Research Center of Aragón (CIBA), Aragón Health Research Institute (IIS Aragón), University of Zaragoza, Zaragoza, Spain; Nanoscience Institute of Aragon (INA), University of Zaragoza, Zaragoza, Spain; Aragón I+D Foundation (ARAID), Government of Aragon, Zaragoza, Spain; Department of Microbiology, Preventive Medicine and Public Health, University of Zaragoza, Zaragoza, Spain.
Hospital Universitario Puerta de Hierro Majadahonda · ESHospital del Mar Research Institute · ESInstituto de Nanociencia y Materiales de Aragón · ESUniversidad de Zaragoza · ESHospital Clínico Universitario Lozano Blesa · ESInserm · FRInstituto Aragonés de Ciencias de la Salud · ESInstituto de Investigación Sanitaria Aragón · ES
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mutational status of
Indexed as
allogeneic NK cellsbad prognosis leukemiachronic lymphocytic leukemialeukemia resistancemismatch
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.